Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease. (28th February 2012)

• Record Type: Journal Article
• Authors: Busaidy, Naifa Lamki; Cabanillas, Maria E.
• Other Names: Xing Mingzhao M. Academic Editor.
• Is Part Of: Journal of thyroid research. Volume 2012(2012)
• Publication Date: 2012-02-28
• Subjects: Thyroid gland -- Cancer -- Periodicals; Thyroid gland -- Diseases -- Periodicals; 616.99444
• DOI: 10.1155/2012/618985
• Languages: English
• ISSNs: 2090-8067

Abstract

Abstract : Differentiated thyroid carcinoma (papillary and follicular) has a favorable prognosis with an 85% 10-year survival. The patients that recur often require surgery and further radioactive iodine to render them disease-free. Five percent of thyroid cancer patients, however, will eventually succumb to their disease. Metastatic thyroid cancer is treated with radioactive iodine if the metastases are radioiodine avid. Cytotoxic chemotherapies for advanced or metastatic noniodine avid thyroid cancers show no prolonged responses and in general have fallen out of favor. Novel targeted therapies have recently been discovered that have given rise to clinical trials for thyroid cancer. Newer aberrations in molecular pathways and oncogenic mutations in thyroid cancer together with the role of angiogenesis in tumor growth have been central to these discoveries. This paper will focus on the management and treatment of metastatic differentiated thyroid cancers that do not take up radioactive iodine.